Mersana Therapeutics Inc (MRSN)

$7.41 +0.25 (3.49%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	35.73M
Revenue (ttm)	40.50M
Net Income (ttm)	-69.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-170.84%
Debt to Equity Ratio	-0.66

Volume	77,166
Avg Vol	120,980
Day's Range	N/A - N/A
Shares Out	4.99M
Stochastic %K	78%
Beta	0.83
Analysts	Strong Sell
Price Target	$28.29

Company Profile

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and dev...

Industry: Biotechnology

Sector: Healthcare

Phone: (617) 498-0020

Website: www.mersana.com

Address:

840 Memorial Drive, Cambridge, United States